Should I buy or sell Acasti Pharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACST shares. View ACST analyst ratings or view top-rated stocks .

What is Acasti Pharma's stock price target for 2024?

1 brokerages have issued twelve-month target prices for Acasti Pharma's stock. Their ACST share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 109.1% from the stock's current price. View analysts price targets for ACST or view top-rated stocks among Wall Street analysts .

How have ACST shares performed in 2024?

Acasti Pharma's stock was trading at $2.89 on January 1st, 2024. Since then, ACST stock has decreased by 0.7% and is now trading at $2.87. View the best growth stocks for 2024 here .

Are investors shorting Acasti Pharma?

Acasti Pharma saw a decline in short interest in March. As of March 31st, there was short interest totaling 1,400 shares, a decline of 78.8% from the March 15th total of 6,600 shares. Based on an average daily trading volume, of 29,300 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company's shares are short sold. View Acasti Pharma's Short Interest .

When is Acasti Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, June 28th 2024. View our ACST earnings forecast .

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) announced its quarterly earnings results on Monday, February, 12th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02.

When did Acasti Pharma's stock split?

Acasti Pharma's stock reverse split on the morning of Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB) , SCYNEXIS (SCYX) , Outlook Therapeutics (OTLK) , Bionano Genomics (BNGO) , Sorrento Therapeutics (SRNE) , ADMA Biologics (ADMA) , Heat Biologics (HTBX) , KushCo (KSHB) , Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS) .

How do I buy shares of Acasti Pharma?

Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ACST

Acasti Pharma (ACST) Stock Price, News & Analysis

→ Forget NVIDIA, buy this $2 AI stock now… (From Behind the Markets) (Ad)

Free ACST Stock Alerts

$2.87

-0.20 (-6.51%)

(As of 04:20 PM ET)

Compare

Today's Range: $2.87
▼
$3.08
50-Day Range: $2.45
▼
$3.48
52-Week Range: $1.72
▼
$3.84

Volume: 19,764 shs
Average Volume: 27,014 shs
Market Capitalization: $26.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Get Acasti Pharma alerts:

Acasti Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 109.1% Upside
$6.00 Price Target
Short Interest: Healthy
0.02% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.44) to ($1.29) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.47 out of 5 stars

Medical Sector

338th out of 918 stocks

Pharmaceutical Preparations Industry

144th out of 416 stocks

3.5

Analyst's Opinion

Consensus Rating
Acasti Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Acasti Pharma has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.02% of the float of Acasti Pharma has been sold short.
Short Interest Ratio / Days to Cover
Acasti Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Acasti Pharma has recently decreased by 78.79%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Acasti Pharma does not currently pay a dividend.
Dividend Growth
Acasti Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACST.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Acasti Pharma this week, compared to 0 articles on an average week.
Search Interest
4 people have searched for ACST on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Acasti Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.51% of the stock of Acasti Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 6.08% of the stock of Acasti Pharma is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Acasti Pharma are expected to grow in the coming year, from ($1.44) to ($1.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Acasti Pharma is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Acasti Pharma is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Acasti Pharma has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Acasti Pharma Stock (NASDAQ:ACST)

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

ACST Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACST Stock News Headlines

April 18, 2024 | americanbankingnews.com

Acasti Pharma (NASDAQ:ACST) Stock Passes Above 200-Day Moving Average of $2.73

April 11, 2024 | americanbankingnews.com

Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Down 78.8% in March

April 19, 2024 | Behind the Markets (Ad)

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

December 14, 2023 | morningstar.com

Acasti Pharma Inc Class A

December 13, 2023 | finance.yahoo.com

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

November 13, 2023 | finance.yahoo.com

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

October 18, 2023 | markets.businessinsider.com

Optimistic Outlook for Acasti Pharma’s GTX-104: Assessing Buy Rating and Potential Impact on Aneurysmal Subarachnoid Hemorrhage Treatment

October 4, 2023 | finance.yahoo.com

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

April 19, 2024 | Behind the Markets (Ad)

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

September 27, 2023 | seekingalpha.com

Acasti announces $7.5M private placement equity funding

July 12, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Acasti Pharma (ACST), ImmunoPrecise Antibodies (IPA)

July 7, 2023 | markets.businessinsider.com

Acasti Pharma: Reverse Stock Split To Become Effective July 10

July 7, 2023 | finance.yahoo.com

Acasti Pharma Announces 1-for-6 Reverse Stock Split

July 5, 2023 | finance.yahoo.com

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

June 23, 2023 | msn.com

Recap: Acasti Pharma Q4 Earnings

May 10, 2023 | finance.yahoo.com

We're Hopeful That Acasti Pharma (NASDAQ:ACST) Will Use Its Cash Wisely

May 8, 2023 | finance.yahoo.com

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

April 4, 2023 | finance.yahoo.com

Acasti Announces Appointment of Prashant Kohli as CEO

April 4, 2023 | finance.yahoo.com

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

March 30, 2023 | finance.yahoo.com

When Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit?

March 30, 2023 | finance.yahoo.com

Acasti Pharma Inc. Announces the Resignation of a Director

March 13, 2023 | finance.yahoo.com

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

February 13, 2023 | msn.com

Acasti Pharma's Earnings Outlook

February 7, 2023 | finance.yahoo.com

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

January 25, 2023 | finance.yahoo.com

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

January 17, 2023 | finance.yahoo.com

Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

January 5, 2023 | finance.yahoo.com

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

See More Headlines

Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/12/2024
Today: 4/19/2024
Next Earnings (Estimated): 6/28/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ACST
CUSIP: N/A
CIK: 1444192
Web: www.acastipharma.com
Phone: 45-0686-4555
Fax: 45-0687-2272
Employees: 32
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $6.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +96.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.0792)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,430,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -13.18%
Return on Assets: -11.32%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.19
Quick Ratio: 15.19

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.14 per share
Price / Book: 0.33

Miscellaneous

Outstanding Shares: 9,400,000
Free Float: 8,129,000
Market Cap: $28.76 million
Optionable: Not Optionable
Beta: 1.49

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Prashant Kohli (Age 52)
CEO & Director
Comp: $358.41k
Mr. Robert J. DelAversano CPA (Age 52)
Principal Financial & Accounting Officer
Dr. R. Loch MacDonald M.D. (Age 62)
Ph.D., Member of Scientific Advisory Board & Chief Medical Officer
Mr. Amresh Kumar Ph.D. (Age 44)
VP of Program Management
Ms. Carrie D'Andrea (Age 52)
VP of Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACST Stock Analysis - Frequently Asked Questions

Should I buy or sell Acasti Pharma stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACST shares.
View ACST analyst ratings or view top-rated stocks.
What is Acasti Pharma's stock price target for 2024?: 1 brokerages have issued twelve-month target prices for Acasti Pharma's stock. Their ACST share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 109.1% from the stock's current price.
View analysts price targets for ACST or view top-rated stocks among Wall Street analysts.
How have ACST shares performed in 2024?: Acasti Pharma's stock was trading at $2.89 on January 1st, 2024. Since then, ACST stock has decreased by 0.7% and is now trading at $2.87.
View the best growth stocks for 2024 here.
Are investors shorting Acasti Pharma?: Acasti Pharma saw a decline in short interest in March. As of March 31st, there was short interest totaling 1,400 shares, a decline of 78.8% from the March 15th total of 6,600 shares. Based on an average daily trading volume, of 29,300 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company's shares are short sold.
View Acasti Pharma's Short Interest.
When is Acasti Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, June 28th 2024.
View our ACST earnings forecast.

How were Acasti Pharma's earnings last quarter?: Acasti Pharma Inc. (NASDAQ:ACST) announced its quarterly earnings results on Monday, February, 12th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02.
When did Acasti Pharma's stock split?: Acasti Pharma's stock reverse split on the morning of Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.
What other stocks do shareholders of Acasti Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).
How do I buy shares of Acasti Pharma?: Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACST) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial